The role of Kaposi sarcoma-associated herpesvirus in the pathogenesis of Kaposi sarcoma

Journal of Pathology

Volumn 235, Issue 2, 2015, Pages 368-380

  Gramolelli, Silvia ^a   Schulz, Thomas F ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Aberrant angiogenesis; Atypical differentiation; Inflammation; Invasiveness; Kaposi sarcoma; KSHV; Oncogenesis

Indexed keywords

VIRUS PROTEIN;

ANGIOGENESIS; ARTICLE; CANCER THERAPY; CARCINOGENESIS; CELL PROLIFERATION; CELL TRANSDIFFERENTIATION; ENDOTHELIUM CELL; HISTOPATHOLOGY; HUMAN; HUMAN HERPESVIRUS 8; INFLAMMATION; INFLAMMATORY INFILTRATE; KAPOSI SARCOMA; METASTASIS; MOLECULAR BIOLOGY; NONHUMAN; PROTEIN EXPRESSION; TUMOR INVASION; ANIMAL; CELL DIFFERENTIATION; GENETICS; HERPESVIRIDAE INFECTIONS; HOST PATHOGEN INTERACTION; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOGENICITY; PATHOLOGY; RISK FACTOR; SARCOMA, KAPOSI; SKIN NEOPLASMS; VIROLOGY; VIRULENCE; VIRUS CELL TRANSFORMATION;

ANIMALS; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL TRANSFORMATION, VIRAL; ENDOTHELIAL CELLS; HERPESVIRIDAE INFECTIONS; HERPESVIRUS 8, HUMAN; HOST-PATHOGEN INTERACTIONS; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; RISK FACTORS; SARCOMA, KAPOSI; SKIN NEOPLASMS; VIRULENCE;

EID: 84917690896     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4441     Document Type: Article

References (163)

1. Braun M. Classics in oncology. Idiopathic multiple pigmented sarcoma of the skin by Kaposi. CA Cancer J Clin 1982; 32: 340-347.
2. Davis J. Kaposi's sarcoma. Present concept of clinical course and treatment. N Y State J Med 1968; 68: 2067-2073.
3. Rothman S. Medical research in Africa. Geographic pathology, Kaposi's sarcoma, and cutaneous physiology of pachyderms. Arch Dermatol 1962; 85: 311-324.
4. Giraldo G, Beth E, Haguenau F. Herpes-type virus particles in tissue culture of Kaposi's sarcoma from different geographic regions. J Natl Cancer Inst 1972; 49: 1509-1526.
5. Fujiwara H, Hashimoto K, Fujiwara K, et al. Detection of human immunodefciency virus type 1 and human papillomavirus type 16 in acquired immunodefciency syndrome-related and classic Kaposi's sarcoma. Arch Dermatol 1993; 129: 1620-1622.
6. Giraldo G, Buonaguro FM, Beth-Giraldo E. The role of opportunistic viruses in Kaposi's sarcoma (KS) evolution. APMIS Suppl 1989; 8: 62-70.
7. Otu AA. Kaposi's sarcoma and HTLV-III, a study in Nigerian adult males. J R Soc Med 1986; 79: 510-514.
8. Ioachim HL, Dorsett B, Melamed J, et al. Cytomegalovirus, angiomatosis, and Kaposi's sarcoma; new observations of a debated relationship. Mod Pathol 1992; 5: 169-178.
9. Jaffe HW, Choi K, Thomas PA, et al. National case-control study of Kaposi's sarcoma and Pneumocystis carinii pneumonia in homosexual men, part 1. Epidemiologic results. Ann Intern Med 1983; 99: 145-151.
10. Levine AM. AIDS-associated malignant lymphoma. Med Clin N Am 1992; 76: 253-268.
11. Beral V, Peterman TA, Berkelman RL, et al. Kaposi's sarcoma among persons with AIDS; a sexually transmitted infection? Lancet 1990; 335: 123-128.
12. Newton R, Grulich A, Beral V, et al. Cancer and HIV infection in Rwanda. Lancet 1995; 345: 1378-1379.
13. Chang Y, Cesarman E, Pessin MS, et al. Identifcation of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 1994; 266: 1865-1869.
14. Cathomas G, McGandy CE, Terracciano LM, et al. Detection of herpesvirus-like DNA by nested PCR on archival skin biopsy specimens of various forms of Kaposi sarcoma. J Clin Pathol 1996; 49: 631-633.
15. Whitby D, Howard MR, Tenant-Flowers M, et al. Detection of Kaposi's sarcoma associated herpesvirus in peripheral blood of HIV-infected individuals and progression to Kaposi's sarcoma. Lancet 1995; 346: 799-802.
16. O'Brien TR, Kedes D, Ganem D, et al. Evidence for concurrent epidemics of human herpesvirus 8 and human immunodefciency virus type 1 in US homosexual men, rates, risk factors, and relationship to Kaposi's sarcoma. J Infect Dis 1999; 180: 1010-1017.
17. Cesarman E, Chang Y, Moore PS, et al. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl J Med 1995; 332: 1186-1191.
18. Soulier J, Grollet L, Oksenhendler E, et al. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castle-man's disease. Blood 1995; 86: 1276-1280.
19. Biological agents. Volume 100 B. A review of human carcinogens. IARC Monogr Eval Carcinog Risks Hum 2012; 100: 1-441.
20. Dedicoat M, Newton R. Review of the distribution of Kaposi's sarcoma-associated herpesvirus (KSHV) in Africa in relation to the incidence of Kaposi's sarcoma. Br J Cancer 2003; 88: 1-3.
21. Mendez JC, Paya CV. Kaposi's sarcoma and transplantation. Herpes 2000; 7: 18-23.
22. Wood NH, Feller L. The malignant potential of HIV-associated Kaposi sarcoma. Cancer Cell Int 2008; 8: 14.
23. Kaaya EE, Parravicini C, Sundelin B, et al. Spindle cell ploidy and proliferation in endemic and epidemic African Kaposi's sarcoma. Eur J Cancer 1992; 28A: 1890-1894.
24. Orenstein JM. Ultrastructure of Kaposi sarcoma. Ultrastruct Pathol 2008; 32: 211-220.
25. Ciufo DM, Cannon JS, Poole LJ, et al. Spindle cell conversion by Kaposi's sarcoma-associated herpesvirus, formation of colonies and plaques with mixed lytic and latent gene expression in infected primary dermal microvascular endothelial cell cultures. J Virol 2001; 75: 5614-5626.
26. Ojala PM, Schulz TF. Manipulation of endothelial cells by KSHV; implications for angiogenesis and aberrant vascular differentiation. Semin Cancer Biol 2014; 26: 69-77.
27. Ensoli B, Sturzl M. HHV-8 and multistep tumorigenesis. Trends Microbiol 1999; 7: 310-312.
28. Roth WK, Werner S, Schirren CG, et al. Depletion of PDGF from serum inhibits growth of AIDS-related and sporadic Kaposi's sarcoma cells in culture. Oncogene 1989; 4: 483-487.
29. Ensoli B, Sturzl M, Monini P. Cytokine-mediated growth promotion of Kaposi's sarcoma and primary effusion lymphoma. Semin Cancer Biol 2000; 10: 367-381.
30. Salahuddin SZ, Nakamura S, Biberfeld P, et al. Angiogenic properties of Kaposi's sarcoma-derived cells after long-term culture in vitro. Science 1988; 242: 430-433.
31. Renne R, Blackbourn D, Whitby D, et al. Limited transmission of Kaposi's sarcoma-associated herpesvirus in cultured cells. J Virol 1998; 72: 5182-5188.
32. + patients. Nat Med 1995; 1: 65-68.
33. Hong YK, Foreman K, Shin JW, et al. Lymphatic reprogramming of blood vascular endothelium by Kaposi sarcoma-associated herpesvirus. Nat Genet 2004; 36: 683-685.
34. Wang HW, Trotter MW, Lagos D, et al. Kaposi sarcoma herpesvirus-induced cellular reprogramming contributes to the lymphatic endothelial gene expression in Kaposi sarcoma. Nat Genet 2004; 36: 687-693.
35. Cheng F, Pekkonen P, Laurinavicius S, et al. KSHV-initiated notch activation leads to membrane-type-1 matrix metalloproteinase-dependent lymphatic endothelial-to-mesenchymal transition. Cell Host Microbe 2011; 10: 577-590.
36. Gasperini P, Espigol-Frigole G, McCormick PJ, et al. Kaposi sarcoma herpesvirus promotes endothelial-to-mesenchymal transition through Notch-dependent signaling. Cancer Res 2012; 72: 1157-1169.
37. Cheng F, Pekkonen P, Ojala PM. Instigation of Notch signaling in the pathogenesis of Kaposi's sarcoma-associated herpesvirus and other human tumor viruses. Future Microbiol 2012; 7: 1191-1205.
38. Alkharsah KR, Singh VV, Bosco R, et al. Deletion of Kaposi's sarcoma-associated herpesvirus FLICE inhibitory protein, v FLIP, from the viral genome compromises the activation of STAT1-responsive cellular genes and spindle cell formation in endothelial cells. J Virol 2011; 85: 10375-10388.
39. Grossmann C, Podgrabinska S, Skobe M, et al. Activation of NF-κB by the latent vFLIP gene of Kaposi's sarcoma-associated herpesvirus is required for the spindle shape of virus-infected endothe-lial cells and contributes to their proinfammatory phenotype. J Virol 2006; 80: 7179-7185.
40. Romero LI, Zhang DN, Herron GS, et al. Interleukin-1 induces major phenotypic changes in human skin microvascular endothelial cells. J Cell Physiol 1997; 173: 84-92.
41. Rieder F, Kessler SP, West GA, et al. Infammation-induced endothelial-to-mesenchymal transition, a novel mechanism of intestinal fbrosis. Am J Pathol 2011; 179, 2660-2673.
42. Potenta S, Zeisberg E, Kalluri R. The role of endothelial-to-mesenchymal transition in cancer progression. Br J Cancer 2008; 99: 1375-1379.
43. Zeisberg EM, Potenta S, Xie L, et al. Discovery of endothelial to mesenchymal transition as a source for carcinoma-associated fbroblasts. Cancer Res 2007; 67: 10123-10128.
44. Zeisberg EM, Tarnavski O, Zeisberg M, et al. Endothelial-to-mesenchymal transition contributes to cardiac fbrosis. Nat Med 2007; 13: 952-961.
45. Lin F, Wang N, Zhang TC. The role of endothelial-mesenchymal transition in development and pathological process. IUBMB Life 2012; 64: 717-723.
46. Rieder F, Kessler SP, West GA, et al. Infammation-induced endothelial-to-mesenchymal transition, a novel mechanism of intestinal fbrosis. Am J Pathol 2011; 179: 2660-2673.
47. Judde JG, Lacoste V, Briere J, et al. Monoclonality or oligo-clonality of human herpesvirus 8 terminal repeat sequences in Kaposi's sarcoma and other diseases. J Natl Cancer Inst 2000; 92: 729-736.
48. Gill PS, Tsai YC, Rao AP, et al. Evidence for multiclonality in multicentric Kaposi's sarcoma. Proc Natl Acad Sci USA 1998; 95: 8257-8261.
49. Delabesse E, Oksenhendler E, Lebbe C, et al. Molecular analysis of clonality in Kaposi's sarcoma. J Clin Pathol 1997; 50: 664-668.
50. Jones T, Ye F, Bedolla R, et al. Direct and effcient cellular transformation of primary rat mesenchymal precursor cells by KSHV. J Clin Invest 2012; 122: 1076-1081.
51. Mutlu AD, Cavallin LE, Vincent L, et al. In vivo-restricted and reversible malignancy induced by human herpesvirus-8 KSHV: a cell and animal model of virally induced Kaposi's sarcoma. Cancer Cell 2007; 11: 245-258.
52. An FQ, Folarin HM, Compitello N, et al. Long-term-infected telomerase-immortalized endothelial cells, a model for Kaposi's sarcoma-associated herpesvirus latency in vitro and in vivo. J Virol 2006; 80: 4833-4846.
53. Staskus KA, Zhong W, Gebhard K, et al. Kaposi's sarcoma-associated herpesvirus gene expression in endothelial (spindle) tumor cells. J Virol 1997; 71: 715-719.
54. Glesby MJ, Hoover DR, Weng S, et al. Use of antiherpes drugs and the risk of Kaposi's sarcoma, data from the Multicenter AIDS Cohort Study. J Infect Dis 1996; 173: 1477-1480.
55. Mocroft A, Youle M, Gazzard B, et al. Anti-herpesvirus treatment and risk of Kaposi's sarcoma in HIV infection. Royal Free/Chelsea and Westminster Hospitals Collaborative Group. AIDS 1996; 10: 1101-1105.
56. Martin D, Gutkind JS. Human tumor-associated viruses and new insights into the molecular mechanisms of cancer. Oncogene 2008; 27(suppl 2), S31-42.
57. Chandriani S, Ganem D. Host transcript accumulation during lytic KSHV infection reveals several classes of host responses. PLoS One 2007; 2: e811.
58. Ganem D. KSHV infection and the pathogenesis of Kaposi's sarcoma. Annu Rev Pathol 2006; 1: 273-296.
59. Rainbow L, Platt GM, Simpson GR, et al. The 222-234 kDa latent nuclear protein (LNA) of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) is encoded by orf73 and is a component of the latency-associated nuclear antigen. J Virol 1997; 71: 5915-5921.
60. Ballestas ME, Kaye KM. Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen 1 mediates episome persistence through cis-acting terminal repeat (TR) sequence and specifcally binds TR DNA. J Virol 2001; 75: 3250-3258.
61. Cotter MA, 2nd, Robertson ES. The latency-associated nuclear antigen tethers the Kaposi's sarcoma-associated herpesvirus genome to host chromosomes in body cavity-based lymphoma cells. Virol og y 1999; 264: 254-264.
62. Grundhoff A, Ganem D. The latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus permits replication of terminal repeat-containing plasmids. J Virol 2003; 77: 2779-2783.
63. Shamay M, Krithivas A, Zhang J, et al. Recruitment of the de novo DNA methyltransferase Dnmt3a by Kaposi's sarcoma-associated herpesvirus LANA. Proc Natl Acad Sci USA 2006; 103: 14554-14559.
64. Renne R, Barry C, Dittmer D, et al. Modulation of cellular and viral gene expression by the latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus. J Virol 2001; 75: 458-468.
65. Lim C, Sohn H, Gwack Y, et al. Latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus (human herpesvirus-8) binds ATF4/CREB2 and inhibits its transcriptional activation activity. J Gen Virol 2000; 81: 2645-2652.
66. Friborg J, Jr., Kong W, Hottiger MO, et al. p53 inhibition by the LANA protein of KSHV protects against cell death. Nature 1999; 402: 889-894.
67. Radkov SA, Kellam P, Boshoff C. The latent nuclear antigen of Kaposi sarcoma-associated herpesvirus targets the retinoblastoma-E2F pathway and with the oncogene Hras transforms primary rat cells. Nat Med 2000; 6: 1121-1127.
68. Watanabe T, Sugaya M, Atkins AM, et al. Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen prolongs the life span of primary human umbilical vein endothelial cells. J Vi ro l 2003; 77: 6188-6196.
69. Bubman D, Guasparri I, Cesarman E. Deregulation of c-Myc in primary effusion lymphoma by Kaposi's sarcoma herpesvirus latency-associated nuclear antigen. Oncogene 2007; 26: 4979-4986.
70. Liu J, Martin HJ, Liao G, et al. The Kaposi's sarcoma-associated herpesvirus LANA protein stabilizes and activates c-Myc. J Virol 2007; 81: 10451-10459.
71. Li M, Lee H, Yoon DW, et al. Kaposi's sarcoma-associated herpesvirus encodes a functional cyclin. J Virol 1997; 71: 1984-1991.
72. Verschuren EW, Hodgson JG, Gray JW, et al. The role of p53 in suppression of KSHV cyclin-induced lymphomagenesis. Cancer Res 2004; 64: 581-589.
73. Grundhoff A, Ganem D. Mechanisms governing expression of the v-FLIP gene of Kaposi's sarcoma-associated herpesvirus. J Virol 2001; 75: 1857-1863.
74. 1 arrest. Mol Cell Biol 2006; 26: 2430-2440.
75. Swanton C, Mann DJ, Fleckenstein B, et al. Herpes viral cyclin/Cdk6 complexes evade inhibition by CDK inhibitor proteins. Nature 1997; 390: 184-187.
76. Verschuren EW, Jones N, Evan GI. The cell cycle and how it is steered by Kaposi's sarcoma-associated herpesvirus cyclin. J Gen Vi ro l 2004; 85: 1347-1361.
77. Ellis M, Chew YP, Fallis L, et al. Degradation of p27(Kip) cdk inhibitor triggered by Kaposi's sarcoma virus cyclin-cdk6 complex. EMBO J 1999; 18: 644-653.
78. Leidal AM, Cyr DP, Hill RJ, et al. Subversion of autophagy by Kaposi's sarcoma-associated herpesvirus impairs oncogene-induced senescence. Cell Host Microbe 2012; 11: 167-180.
79. Koopal S, Furuhjelm JH, Jarviluoma A, et al. Viral oncogene-induced DNA damage response is activated in Kaposi sarcoma tumorigenesis. PLoS Pathog 2007; 3: 1348-1360.
80. Bieleski L, Talbot SJ. Kaposi's sarcoma-associated herpesvirus vCyclin open reading frame contains an internal ribosome entry site. J Virol 2001; 75: 1864-1869.
81. Wang L, Damania B. Kaposi's sarcoma-associated herpesvirus confers a survival advantage to endothelial cells. Cancer Res 2008; 68: 4640-4648.
82. Hodak E, Hammel I, Feinmesser M, et al. Differential expression of p53 and Ki-67 proteins in classic and iatrogenic Kaposi's sarcoma. Am J Dermatopathol 1999; 21: 138-145.
83. Delgado T, Carroll PA, Punjabi AS, et al. Induction of the Warburg effect by Kaposi's sarcoma herpesvirus is required for the maintenance of latently infected endothelial cells. Proc Natl Acad Sci USA 2010; 107: 10696-10701.
84. Warburg O. On respiratory impairment in cancer cells. Science 1956; 124: 269-270.
85. Warburg O. On the origin of cancer cells. Science 1956; 123: 309-314.
86. Goetze K, Walenta S, Ksiazkiewicz M, et al. Lactate enhances motility of tumor cells and inhibits monocyte migration and cytokine release. Int J Oncol 2011; 39: 453-463.
87. Weiss G, Shemer A, Trau H. The Koebner phenomenon: review of the literature. J Eur Acad Dermatol Venereol 2002; 16: 241-248.
88. Grulich AE, van Leeuwen MT, Falster MO, et al. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 2007; 370: 59-67.
89. Grayson W, Pantanowitz L. Histological variants of cutaneous Kaposi sarcoma. Diagn Pathol 2008; 3: 31.
90. Kaul A, Pearson JD, Petty R, et al. Vascular endothelium, a potential role in HIV infection and the pathogenesis of Kaposi's sarcoma, observations and speculations. Mol Aspects Med 1991; 12: 297-312.
91. Muller H, Kaya S, Stutte HJ. Growth patterns, infammatory cells and prognosis in AIDS-associated Kaposi's sarcoma. Res Virol 1990; 141: 201-207.
92. Barillari G, Gendelman R, Gallo RC, et al. The Tat proteinof human immunodefciency virus type 1, a growth factor for AIDS Kaposi sarcoma and cytokine-activated vascular cells, induces adhesion of the same cell types by using integrin receptors recognizing the RGD amino acid sequence. Proc Natl Acad Sci USA 1993; 90: 7941-7945.
93. Monini P, Colombini S, Sturzl M, et al. Reactivation and persistence of human herpesvirus-8 infection in B cells and monocytes by Th-1 cytokines increased in Kaposi's sarcoma. Blood 1999; 93: 4044-4058.
94. Monini P, Carlini F, Sturzl M, et al. α-Interferon inhibits human herpesvirus 8 (HHV-8) reactivation in primary effusion lymphoma cells and reduces HHV-8 load in cultured peripheral blood mononu-clear cells. J Virol 1999; 73: 4029-4041.
95. Cheng F, Weidner-Glunde M, Varjosalo M, et al. KSHV reactivation from latency requires Pim-1 and Pim-3 kinases to inactivate the latency-associated nuclear antigen LANA. PLoS Pathog 2009; 5: e1000324.
96. Sirianni MC, Vincenzi L, Fiorelli V, et al. γ-Interferon production in peripheral blood mononuclear cells and tumor infltrating lymphocytes from Kaposi's sarcoma patients, correlation with the presence of human herpesvirus-8 in peripheral blood mononuclear cells and lesional macrophages. Blood 1998; 91: 968-976.
97. Rizzardini G, Piconi S, Ruzzante S, et al. Immunological activation markers in the serum of African and European HIV-seropositive and seronegative individuals. AIDS 1996; 10: 1535-1542.
98. Ensoli B, Sgadari C, Barillari G, et al. Biology of Kaposi's sarcoma. Eur J Cancer 2001; 37: 1251-1269.
99. Kledal TN, Rosenkilde MM, Coulin F, et al. A broad-spectrum chemokine antagonist encoded by Kaposi's sarcoma-associated herpesvirus. Science 1997; 277: 1656-1659.
100. Weber KS, Grone HJ, Rocken M, et al. Selective recruitment of Th2-type cells and evasion from a cytotoxic immune response mediated by viral macrophage inhibitory protein-II. Eur J Immunol 2001; 31: 2458-2466.
101. Stine JT, Wood C, Hill M, et al. KSHV-encoded CC chemokine vMIP-III is a CCR4 agonist, stimulates angiogenesis, and selectively chemoattracts TH2 cells. Blood 2000; 95: 1151-1157.
102. Smith WL. Prostanoid biosynthesis and mechanisms of action. Am J Physiol 1992; 263: F181-191.
103. Williams CS, DuBois RN. Prostaglandin endoperoxide synthase, why two isoforms? Am J Physiol 1996; 270: G393-400.
104. Hwang D, Scollard D, Byrne J, et al. Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J Natl Cancer Inst 1998; 90: 455-460.
105. Tsujii M, Kawano S, DuBois RN. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA 1997; 94: 3336-3340.
106. Tucker ON, Dannenberg AJ, Yang EK, et al. Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Res 1999; 59: 987-990.
107. Kulkarni S, Rader JS, Zhang F, et al. Cyclooxygenase-2 is over-expressed in human cervical cancer. Clin Cancer Res 2001; 7: 429-434.
108. Nunez O, Fernandez-Martinez A, Majano PL, et al. Increased intra-hepatic cyclooxygenase 2, matrix metalloproteinase 2, and matrix metalloproteinase 9 expression is associated with progressive liver disease in chronic hepatitis C virus infection, role of viral core and NS5A proteins. Gut 2004; 53: 1665-1672.
109. Sharma-Walia N, Paul AG, Bottero V, et al. Kaposi's sarcoma-associated herpesvirus (KSHV)-induced COX-2, a key factor in latency, infammation, angiogenesis, cell survival and invasion. PLoS Pathog 2010; 6: e1000777.
110. Sharma-Walia N, Patel K, Chandran K, et al. COX-2/PGE2, molecular ambassadors of Kaposi's sarcoma-associated herpes virus oncoprotein-v-FLIP. Oncogenesis 2012; 1: e5.
111. Haas DA, Bala K, Busche G, et al. The infammatory kinase MAP4K4 promotes reactivation of Kaposi's sarcoma herpesvirus and enhances the invasiveness of infected endothelial cells. PLoS Pa t h o g 2013; 9: e1003737.
112. Douglas JL, Gustin JK, Dezube B, et al. Kaposi's sarcoma, a model of both malignancy and chronic infammation. Panminerva Med 2007; 49: 119-138.
113. Wang L, Dittmer DP, Tomlinson CC, et al. Immortalization of primary endothelial cells by the K1 protein of Kaposi's sarcoma-associated herpesvirus. Cancer Res 2006; 66: 3658-3666.
114. Qian LW, Xie J, Ye F, et al. Kaposi's sarcoma-associated herpesvirus infection promotes invasion of primary human umbilical vein endothelial cells by inducing matrix metalloproteinases. J Virol 2007; 81: 7001-7010.
115. He M, Zhang W, Bakken T, et al. Cancer angiogenesis induced by Kaposi sarcoma-associated herpesvirus is mediated by EZH2. Cancer Res 2012; 72: 3582-3592.
116. Qin Z, Dai L, Slomiany MG, et al. Direct activation of emmprin and associated pathogenesis by an oncogenic herpesvirus. Cancer Res 2012; 70: 3884-3889.
117. Dai L, Bratoeva M, Toole BP, et al. KSHV activation of VEGF secretion and invasion for endothelial cells is mediated through viral upregulation of emmprin-induced signal transduction. Int J Cancer 2010; 131: 834-843.
118. Wang X, He Z, Xia T, et al. Latency-associated nuclear antigen of Kaposi sarcoma-associated herpesvirus promotes angiogenesis through targeting Notch signaling effector Hey1. Cancer Res 2014; 74: 2026-2037.
119. Sturzl M, Brandstetter H, Zietz C, et al. Identifcation of interleukin-1 and platelet-derived growth factor-B as major mitogens for the spindle cells of Kaposi's sarcoma, a combined in vitro and in vivo analysis. Oncogene 1995; 10: 2007-2016.
120. Sturzl M, Roth WK, Brockmeyer NH, et al. Expression of platelet-derived growth factor and its receptor in AIDS-related Kaposi sarcoma in vivo suggests paracrine and autocrine mechanisms of tumor maintenance. Proc Natl Acad Sci USA 1992; 89: 7046-7050.
121. Gallaher AM, Das S, Xiao Z, et al. Proteomic screening of human targets of viral microRNAs reveals functions associated with immune evasion and angiogenesis. PLoS Pathog 2013; 9: e1003584.
122. Gunther T, Grundhoff A. The epigenetic landscape of latent Kaposi sarcoma-associated herpesvirus genomes. PLoS Pathog 2010; 6: e1000935.
123. Chandriani S, Ganem D. Array-based transcript profling and limiting-dilution reverse transcription-PCR analysis identify additional latent genes in Kaposi's sarcoma-associated herpesvirus. J Virol 2010; 84: 5565-5573.
124. Glenn M, Rainbow L, Aurade F, et al. Identifcation of a spliced gene from Kaposi's sarcoma-associated herpesvirus encoding a protein with similarities to latent membrane proteins 1 and 2A of Epstein-Barr virus. J Virol 1999; 73: 6953-6963.
125. Parravicini C, Chandran B, Corbellino M, et al. Differential viral protein expression in Kaposi's sarcoma-associated herpesvirus-infected diseases, Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's disease. Am J Pathol 2000; 156: 743-749.
126. Katano H, Sato Y, Kurata T, et al. Expression and localization of human herpesvirus 8-encoded proteins in primary effusion lymphoma, Kaposi's sarcoma, and multicentric Castleman's disease. Virology 2000; 269: 335-344.
127. Lee BS, Lee SH, Feng P, et al. Characterization of the Kaposi's sarcoma-associated herpesvirus K1 signalosome. J Virol 2005; 79: 12173-12184.
128. Yaich S, Charfeddine K, Zaghdane S, et al. Sirolimus for the treatment of Kaposi sarcoma after renal transplantation, a series of 10 cases. Transpl Proc 2012; 44: 2824-2826.
129. Poole LJ, Zong JC, Ciufo DM, et al. Comparison of genetic variability at multiple loci across the genomes of the major subtypes of Kaposi's sarcoma-associated herpesvirus reveals evidence for recombination and for two distinct types of open reading frame K15 alleles at the right-hand end. J Virol 1999; 73: 6646-6660.
130. Choi JK, Lee BS, Shim SN, et al. Identifcation of the novel K15 gene at the rightmost end of the Kaposi's sarcoma-associated herpesvirus genome. J Virol 2000; 74: 436-446.
131. Brinkmann MM, Glenn M, Rainbow L, et al. Activation of mitogen-activated protein kinase and NF-κB pathways by a Kaposi's sarcoma-associated herpesvirus K15 membrane protein. J Virol 2003; 77: 9346-9358.
132. Brinkmann MM, Pietrek M, Dittrich-Breiholz O, et al. Modulation of host gene expression by the K15 protein of Kaposi's sarcoma-associated herpesvirus. J Virol 2007; 81: 42-58.
133. Pietrek M, Brinkmann MM, Glowacka I, et al. Role of the Kaposi's sarcoma-associated herpesvirus K15 SH3 binding site in infammatory signaling and B-cell activation. J Virol 2010; 84: 8231-8240.
134. Wang L, Brinkmann MM, Pietrek M, et al. Functional characterization of the M-type K15-encoded membrane protein of Kaposi's sarcoma-associated herpesvirus. J Gen Virol 2007; 88: 1698-1707.
135. Bala K, Bosco R, Gramolelli S, et al. Kaposi's sarcoma herpesvirus K15 protein contributes to virus-induced angiogenesis by recruiting PLCγ1 and activating NFAT1-dependent RCAN1 expression. PLoS Pa t h o g 2012; 8: e1002927.
136. Aoki Y, Jaffe ES, Chang Y, et al. Angiogenesis and hematopoiesis induced by Kaposi's sarcoma-associated herpesvirus-encoded interleukin-6. Blood 1999; 93: 4034-4043.
137. Zhu X, Guo Y, Yao S, et al. Synergy between Kaposi's sarcoma-associated herpesvirus (KSHV) vIL-6 and HIV-1 Nef protein in promotion of angiogenesis and oncogenesis: role of the AKT signaling pathway. Oncogene 2013; 33, 1986-1996.
138. Choi YB, Nicholas J. Autocrine and paracrine promotion of cell survival and virus replication by human herpesvirus 8 chemokines. J Virol 2008; 82: 6501-6513.
139. Zhu X, Guo Y, Yao S, et al. Synergy between Kaposi's sarcoma-associated herpesvirus (KSHV) vIL-6 and HIV-1 Nef protein in promotion of angiogenesis and oncogenesis, role of the AKT signaling pathway. Oncogene 2013; 33: 1986-1996.
140. Mori Y, Nishimoto N, Ohno M, et al. Human herpesvirus 8-encoded interleukin-6 homologue (viral IL-6) induces endogenous human IL-6 secretion. J Med Virol 2000; 61: 332-335.
141. Molden J, Chang Y, You Y, et al. A Kaposi's sarcoma-associated herpesvirus-encoded cytokine homolog (vIL-6) activates signaling through the shared gp130 receptor subunit. J Biol Chem 1997; 272: 19625-19631.
142. Mullberg J, Geib T, Jostock T, et al. IL-6 receptor independent stimulation of human gp130 by viral IL-6. J Immunol 2000; 164: 4672-4677.
143. Meads MB, Medveczky PG. Kaposi's sarcoma-associated herpesvirus-encoded viral interleukin-6 is secreted and modifed differently than human interleukin-6, evidence for a unique autocrine signaling mechanism. J Biol Chem 2004; 279: 51793-51803.
144. Chen D, Choi YB, Sandford G, et al. Determinants of secretion and intracellular localization of human herpesvirus 8 interleukin-6. J Vi ro l 2009; 83: 6874-6882.
145. Chen D, Sandford G, Nicholas J. Intracellular signaling mechanisms and activitiesofhuman herpesvirus8interleukin-6. J Virol 2009; 83: 722-733.
146. Bais C, Santomasso B, Coso O, et al. G-protein-coupled receptor of Kaposi's sarcoma-associated herpesvirus is a viral oncogene and angiogenesis activator. Nature 1998; 391: 86-89.
147. Sodhi A, Montaner S, Gutkind JS. Does dysregulated expression of a deregulated viral GPCR trigger Kaposi's sarcomagenesis? FA S E B J 2004; 18: 422-427.
148. Sodhi A, Montaner S, Patel V, et al. Akt plays a central role in sarcomagenesis induced by Kaposi's sarcoma herpesvirus-encoded G protein-coupled receptor. Proc Natl Acad Sci USA 2004; 101: 4821-4826.
149. Schwarz M, Murphy PM. Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor constitutively activates NF-κB and induces proinfammatory cytokine and chemokine production via a C-terminal signaling determinant. J Immunol 2001; 167: 505-513.
150. Montaner S, Sodhi A, Molinolo A, et al. Endothelial infection with KSHV genes in vivo reveals that vGPCR initiates Kaposi's sarcomagenesis and can promote the tumorigenic potential of viral latent genes. Cancer Cell 2003; 3: 23-36.
151. Holst PJ, Rosenkilde MM, Manfra D, et al. Tumorigenesis induced by the HHV8-encoded chemokine receptor requires ligand modulation of high constitutive activity. J Clin Invest 2001; 108: 1789-1796.
152. Yang TY, Chen SC, Leach MW, et al. Transgenic expression of the chemokine receptor encoded by human herpesvirus 8 induces an angioproliferative disease resembling Kaposi's sarcoma. J Exp Med 2000; 191: 445-454.
153. Boshoff C, Endo Y, Collins PD, et al. Angiogenic and HIV-inhibitory functions of KSHV-encoded chemokines. Science 1997; 278: 290-294.
154. Cherqui S, Kingdon KM, Thorpe C, et al. Lentiviral gene delivery of vMIP-II to transplanted endothelial cells and endothe-lial progenitors is proangiogenic in vivo. Mol Ther 2007; 15: 1264-1272.
155. Liu C, Okruzhnov Y, Li H, et al. Human herpesvirus 8 (HHV-8)-encoded cytokines induce expression of and autocrine signaling by vascular endothelial growth factor (VEGF) in HHV-8-infected primary-effusion lymphoma cell lines and mediate VEGF-independent antiapoptotic effects. J Virol 2001; 75: 10933-10940.
156. Haque NS, Fallon JT, Pan JJ, et al. Chemokine receptor-8 (CCR8) mediates human vascular smooth muscle cell chemotaxis and metalloproteinase-2 secretion. Blood 2004; 103: 1296-1304.
157. Bower M, Dalla Pria A, Coyle C, et al. Prospective stage-stratifed approach to AIDS-related Kaposi's sarcoma. J Clin Oncol 2014; 32: 409-414.
158. Krell J, Stebbing J. Broader implications of a stage-guided stratifed therapeutic approach for AIDS-related Kaposi's sarcoma. J Clin Oncol 2014; 32: 373-375.
159. Willers CP, Reimann G, Mertins L, et al. Infuence of foscarnet on HIV-associated Kaposi's sarcoma-derived cell lines. Eur J Med Res 1999; 4: 514-516.
160. Moses AV, Jarvis MA, Raggo C, et al. Kaposi's sarcoma-associated herpesvirus-induced upregulation of the c-kit proto-oncogene, as identifed by gene expression profling, is essential for the transformation of endothelial cells. J Virol 2002; 76: 8383-8399.
161. Koon HB, Bubley GJ, Pantanowitz L, et al. Imatinib-induced regression of AIDS-related Kaposi's sarcoma. J Clin Oncol 2005; 23: 982-989.
162. Koon HB, Krown SE, Lee JY, et al. Phase II trial of imatinib in AIDS-associated Kaposi's sarcoma, AIDS Malignancy Consortium Protocol 042. J Clin Oncol 2014; 32: 402-408.
163. Ardavanis A, Doufexis D, Kountourakis P, et al. A Kaposi's sarcoma complete clinical response after sorafenib administration. Ann Oncol 2008; 19: 1658-1659.